LANSOPRAZOLE TEVA 15 mg enterokapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lansoprazole teva 15 mg enterokapseli, kova

ratiopharm gmbh - lansoprazolum - enterokapseli, kova - 15 mg - lansopratsoli

LANSOPRAZOLE TEVA 30 mg enterokapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lansoprazole teva 30 mg enterokapseli, kova

ratiopharm gmbh - lansoprazolum - enterokapseli, kova - 30 mg - lansopratsoli

SERTRALIN TEVA 50 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sertralin teva 50 mg tabletti, kalvopäällysteinen

ratiopharm gmbh - sertralini hydrochloridum - tabletti, kalvopäällysteinen - 50 mg - sertraliini

SERTRALIN TEVA 100 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

sertralin teva 100 mg tabletti, kalvopäällysteinen

ratiopharm gmbh - sertralini hydrochloridum - tabletti, kalvopäällysteinen - 100 mg - sertraliini

Artiss liuokset kudosliimaa varten Suomi - suomi - Fimea (Suomen lääkevirasto)

artiss liuokset kudosliimaa varten

baxter oy - calcium chloride dihydrate, human fibrinogen, aprotinine, human thrombin - liuokset kudosliimaa varten - yhdistelmävalmisteet

Tisseel liuokset kudosliimaa varten Suomi - suomi - Fimea (Suomen lääkevirasto)

tisseel liuokset kudosliimaa varten

baxter oy - aprotinine, calcium chloride, factor xiii (fibrin stabilising factor), fibrinogen, human thrombin - liuokset kudosliimaa varten - yhdistelmävalmisteet

Zolsketil pegylated liposomal Euroopan unioni - suomi - EMA (European Medicines Agency)

zolsketil pegylated liposomal

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Celdoxome pegylated liposomal Euroopan unioni - suomi - EMA (European Medicines Agency)

celdoxome pegylated liposomal

yes pharmaceutical development services gmbh - doksorubisiinihydrokloridia - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiset aineet - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

NexoBrid Euroopan unioni - suomi - EMA (European Medicines Agency)

nexobrid

mediwound germany gmbh - proteolytic enzymes enriched in bromelain - puhdistus - valmisteet haavojen ja haavaumien hoitoon - nexobrid on tarkoitettu syksyn poistamiseen aikuisilla, joilla on syvä osittainen ja täysipaksuinen lämpöpalovamma.

Fluanxol 0.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

fluanxol 0.5 mg tabletti, kalvopäällysteinen

h. lundbeck a/s - flupentixol dihydrochloride - tabletti, kalvopäällysteinen - 0.5 mg - flupentiksoli